07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Pseudostat oral vaccine data

DLVRY reported Phase II results in 91 patients. The immunization, involving three days of treatment repeated twice at one-month intervals, led to 10 times fewer acute infective episodes compared to placebo. Rates of infection had...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Macrulin encapsulated oral insulin data

DLVRY provided preliminary analysis of a 6-patient, single dose, cross-over Phase II trial. Blood glucose levels were reduced compared to placebo after Macrulin dosing. The reductions of Area Under Curve for blood glucose from 200IU,...
07:00 , Sep 18, 2006 |  BC Week In Review  |  Company News

Bio-Rad Laboratories, Provalis deal

BIO’s Bio-Metrics Ltd. subsidiary completed its previously announced acquisition of PRO’s PB Diagnostics Ltd. medical diagnostic business for about $3 million in cash (see BioCentury, Aug. 14). Bio-Rad Laboratories Inc. (BIO), Hercules, Calif.   Provalis...
07:00 , Sep 11, 2006 |  BioCentury  |  Finance

Ebb & Flow

With some SEK1.2 billion ($165.5 million) in cash in its coffers at June 30, Biovitrum is in no rush to raise additional capital as it seeks to list its shares on the Stockholm Stock Exchange....
07:00 , Aug 14, 2006 |  BC Week In Review  |  Company News

Bio-Rad Laboratories, Provalis deal

BIO's Bio-Metrics Ltd. subsidiary plans to acquire PRO's PB Diagnostics Ltd. medical diagnostic business for £1.6 million ($2.1 million) in cash. PRO's diagnostic business generated sales of £400,000 ($500,000) in the six months ended Dec....
07:00 , Jul 3, 2006 |  BC Week In Review  |  Company News

Provalis, sanofi-aventis deal

SAN purchased PRO's pneumonia vaccine candidates for $1.3 million in cash. PRO halted vaccine R&D in 2002 to focus on diagnostics. Provalis plc (LSE:PRO; PVLSF), Deeside, U.K.   sanofi-aventis Group (Euronext:SAN; SNY), Paris, France  ...
08:00 , Feb 6, 2006 |  BC Week In Review  |  Company News

Galen, Provalis deal

PRO sold its Provalis Healthcare pharmaceuticals division to GAL's Kogen Ltd. subsidiary for £10.5 million ($18.6 million) in cash. PRO said the sale will let it focus on its Medical Diagnostics division. PRO, which announced...
08:00 , Feb 6, 2006 |  BC Week In Review  |  Company News

Provalis board of directors update

Provalis plc (LSE:PRO; PVLSF), Deeside, U.K.   Business: Musculoskeletal, Autoimmune, Diagnostic   Resigning: Frank Harding as chairman; Alan Aikman, a director, will become chairman  ...
08:00 , Jan 2, 2006 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Restructuring watch No fewer than nine public biotech companies cut staff in the fourth quarter, down from 13 in the same period last year. (A) Net loss for 1H05; (B) Operating loss for...
08:00 , Dec 5, 2005 |  BC Week In Review  |  Company News

Provalis board of directors update

Provalis plc (LSE:PRO), Deeside, U.K.   Business: Musculoskeletal, Autoimmune, Diagnostic   Resigned: Christine Soden  ...